Lim Y N, Lim T O, Lee D G, Wong H S, Ong L M, Shaariah W, Rozina G, Morad Z
National Renal Registry Malaysia, 2nd Floor, MMA House, 124, Jalan Pahang, 50286 Kuala Lumpur, Malaysia.
Med J Malaysia. 2008 Sep;63 Suppl C:5-8.
The Malaysian National Renal Registry was set up in 1992 to collect data for patients on renal replacement therapy (RRT). We present here the report of the Malaysian dialysis registry. The objectives of this papar are: (1) To examine the overall provision of dialysis treatment in Malaysia and its trend from 1980 to 2006. (2) To assess the treatment rate according to the states in the country. (3) To describe the method, location and funding of dialysis. (4) To characterise the patients accepted for dialysis treatment. (5) To analyze the outcomes of the dialysis treatment. Data on patients receiving dialysis treatment were collected at initiation of dialysis, at the time of any significant outcome, as well as yearly. The number of dialysis patients increased from 59 in 1980 to almost 15,000 in 2006. The dialysis acceptance rate increased from 3 per million population in 1980 to 116 per million population in 2006, and the prevalence rate from 4 to 550 per million population over the same period. The economically advantaged states of Malaysia had much higher dialysis treatment rates compared to the less economically advanced states. Eighty to 90% of new dialysis patients were accepted into centre haemodialysis (HD), and the rest into the chronic ambulatory peritoneal dialysis (CAPD) programme. The government provided about half of the funding for dialysis treatment. Patients older than 55 years accounted for the largest proportion of new patients on dialysis since the 1990s. Diabetes mellitus has been the main cause of ESRD and accounted for more than 50% of new ESRD since 2002. Annual death rate averaged about 10% on HD and 15% on CAPD. The unadjusted 5-year patient survival on both HD and CAPD was about 80%. Fifty percent of dialysis patients reported very good median QoL index score. About 70% of dialysis patients were about to work full or part time. There has been a very rapid growth of dialysis provision in Malaysia particularly in the older age groups. ESRD caused by diabetes mellitus, despite being a preventable and treatable cause of ESRD--has increased and accounted for more than 50% of incident dialysis patients. Death and survival rates on dialysis are comparable to those from other countries.
马来西亚国家肾脏登记处成立于1992年，旨在收集接受肾脏替代治疗（RRT）患者的数据。我们在此展示马来西亚透析登记处的报告。本文的目的是：（1）研究1980年至2006年马来西亚透析治疗的总体提供情况及其趋势。（2）根据该国各州评估治疗率。（3）描述透析的方法、地点和资金。（4）描述接受透析治疗患者的特征。（5）分析透析治疗的结果。接受透析治疗患者的数据在透析开始时、出现任何重大结果时以及每年进行收集。透析患者数量从1980年的59例增加到2006年的近15000例。透析接受率从1980年的每百万人口3例增加到2006年的每百万人口116例，同期患病率从每百万人口4例增加到550例。马来西亚经济发达的州与经济欠发达的州相比，透析治疗率要高得多。80%至90%的新透析患者被纳入中心血液透析（HD），其余患者纳入持续性非卧床腹膜透析（CAPD）项目。政府提供了约一半的透析治疗资金。自20世纪90年代以来，55岁以上的患者在新透析患者中占比最大。糖尿病一直是终末期肾病（ESRD）的主要病因，自2002年以来占新ESRD病例的50%以上。血液透析的年死亡率平均约为10%，腹膜透析为15%。血液透析和腹膜透析未经调整的5年患者生存率约为80%。50%的透析患者报告生活质量指数中位数得分非常好。约70%的透析患者能够全职或兼职工作。马来西亚的透析服务增长非常迅速，尤其是在老年人群体中。糖尿病导致的ESRD尽管是ESRD的可预防和可治疗病因，但仍在增加，占新透析患者的50%以上。透析的死亡率和生存率与其他国家相当。
